REBYOTA™ Prospective Registry is a study to gather information from patients who have received REBYOTA™ for preventing rCDI, which stands for recurrent Clostridioides difficile infection. This study is observational, meaning doctors decide whether to prescribe REBYOTA™ independently of the study. After patients agree, their medical records will be used to collect data about their health history, CDI episodes, and any related symptoms or treatments over six months.
Key points to know:
- The study lasts for 6 months with data collected from medical records.
- Participants must be 18 or older and have completed antibiotic treatment for rCDI.
- Patients are not part of any other clinical trials to join this study.
This research helps understand how REBYOTA™ works in real-life settings without changing any treatments. By joining, you won't have to make extra visits or follow a special treatment plan beyond what your doctor advises.